Physiologically Based Biopharmaceutics Modeling for Gefapixant IR Formulation Development and Defining the Bioequivalence Dissolution Safe Space
Authors:
- 11 June 2024
- journal article
- research article
- Published by Springer Nature in The AAPS Journal
- Vol. 26 (4) , 1-12
Abstract
Gefapixant is a weakly basic drug which has been formulated as an immediate release tablet for oral administration. A physiologically based biopharmaceuticKeywords
This publication has 21 references indexed in Scilit:
- Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New DrugsThe AAPS Journal, 2021
- Applications of Physiologically Based Biopharmaceutics Modeling (PBBM) to Support Drug Product Quality: A Workshop Summary ReportJournal of Pharmaceutical Sciences, 2021
- Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018‐2019 Submissions to the US FDA's Office of Clinical PharmacologyThe Journal of Clinical Pharmacology, 2020
- Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juicesEuropean Journal of Pharmaceutics and Biopharmaceutics, 2019
- Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Link—a Workshop Summary ReportThe AAPS Journal, 2019
- PBPK Absorption Modeling: Establishing the In Vitro–In Vivo Link—Industry PerspectiveThe AAPS Journal, 2019
- Prediction of ARA/PPI Drug-Drug Interactions at the Drug Discovery and Development InterfaceJournal of Pharmaceutical Sciences, 2019
- Physiologically Based Absorption Modeling of Salts of Weak Bases Based on Data in Hypochlorhydric and Achlorhydric Biorelevant MediaAAPS PharmSciTech, 2018
- UV imaging in pharmaceutical analysisJournal of Pharmaceutical and Biomedical Analysis, 2018
- The Role of Physiologically Based Oral Absorption Modelling in Formulation Development Under a Quality by Design ParadigmJournal of Pharmaceutical Sciences, 2017